title: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

acronym: Phase II MK-3475 in subjects with  previously treated Hepatocellular Carcinoma

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title:
A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa

 Etude multicentrique, randomisée, en double aveugle, contrôlée par placebo, conçue en plateforme, évaluant l’efficacité et la sécurité d’emploi de l’iscalimab (CFZ533) et de LYS006 chez des patients atteints d’hidradénite suppurée modérée à sévère

acronym: Efficacy and safety of different investigational drugs for the treatment of hidradenitis suppurativa

source: euctr

lead_sponsor: Novartis Pharma AG

study_type: Interventional

status: Ongoing

lead_sponsor_type: industriel

status_simplified: Ongoing


title:
Pragmatic, prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of a 6% Hydroxyethyl starch  (HES) solution versus an electrolyte solution in trauma patients

 Étude pragmatique, prospective, randomisée, contrôlée, en double aveugle, multicentrique, internationale, visant à évaluer la sécurité et l’efficacité d’une solution d’hydroxyéthylamidon (HEA) à 6 % par comparaison avec une solution électrolytique chez des patients victimes de blessures traumatiques

acronym: TETHYS

lead_sponsor: B. Braun Melsungen AG


title: AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETACOPLAN IN THE TREATMENT OF POST-TRANSPLANT RECURRENCE OF C3G OR IC‑MPGN

acronym: NOBLE

lead_sponsor: Apellis Pharmaceuticals, Inc.


title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis

lead_sponsor: Applied Molecular Transport Inc.


title:
A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing surgery or delivery

 Étude prospective de phase 3, multicentrique, en ouvert, non contrôlée, visant à évaluer l’efficacité, la sécurité d’emploi et la pharmacocinétique d’Atenativ chez des patients atteints d’un déficit congénital en antithrombine nécessitant une intervention chirurgicale ou un accouchement

lead_sponsor: Octapharma AG


title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)

acronym: ADDRESS

lead_sponsor: argenx BV


title: Open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD patients who have been previously treated in one of the GIVINOSTAT studies

acronym: Givinostat DMD long term study

lead_sponsor: ITALFARMACO S.p.A.

status_simplified: Unknown


title:
An open label, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed PNH Phase 2 and Phase 3 studies with iptacopan.

 Etude d’extension en ouvert, multicentrique, ayant pour but de caractériser la tolérance et la sécurité d’emploi à long terme de l’iptacopan (LNP023) chez des patients atteints d’hémoglobinurie paroxystique nocturne (HPN) ayant terminé des études de phase II et III évaluant l’iptacopan


title: A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)

acronym: MOTION

lead_sponsor: Deciphera Pharmaceuticals, LLC


title: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial

acronym: Ship-CT study

lead_sponsor: Erasmus MC

status: Completed

status_simplified: Completed


title: A Phase 2, single-arm, pathologist-blinded study using liver biopsy specimens to assess copper concentration and histopathologic changes in patients with Wilson disease who are treated with ALXN1840 for 48 weeks followed by an extension treatment period with ALXN1840 for up to an additional 48 weeks

lead_sponsor: Alexion Pharmaceuticals, Inc


title:
A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment

  Un essai en double aveugle, randomisé, contrôlé par placebo portant sur le traitement d’appoint à base de ganaxolone chez des enfants de sexe féminin atteints d’épilepsie liée à la protocadhérine 19 (PCDH19) suivi d’un traitement à long terme en ouvert

lead_sponsor: Marinus Pharmaceuticals, Inc.


title:
Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patients with an inadequate response to ursodeoxycholic acid

 Étude de détermination de la dose, en double aveugle, randomisée, contrôlée par placebo, de phase II, comparant différentes doses de comprimés d’acide norucholique avec un placebo dans le traitement de la cholangite biliaire primitive chez des patients présentant une réponse inadéquate à l’acide ursodésoxycholique

acronym: NCA vs. placebo in PBC

lead_sponsor: Dr. Falk Pharma GmbH


title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial Pneumonia

lead_sponsor: Aridis Pharmaceuticals, Inc.


title:
A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label Extension
 The EPSILON Study: Early Parkinson wIth L-DOPA/DDCI and Opicapone

acronym: EPSILON

lead_sponsor: BIAL – Portela & Cª, S.A.


title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL,  CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF  ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH AN ANTI-PD-L1/PD-1 ANTIBODY AND PLATINUM-CONTAINING CHEMOTHERAPY

lead_sponsor: F. Hoffman-La Roche Ltd.


title: A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age

acronym: Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of age

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc


title: A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when Administered as Weekly Oral Doses in Participants with Early Manifest Huntington’s Disease


title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia

lead_sponsor: Kartos Therapeutics Inc.


title: A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia

lead_sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc


title: A Multicenter, Randomized, Double-blind, Placebo- and Active controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophrenia

lead_sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.


title:
RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

 RINGSIDE : Étude multicentrique randomisée de phase II/III visant à évaluer l’AL102 chez des patients atteints de tumeurs desmoïdes évolutives.

acronym: RINGSIDE

lead_sponsor: Ayala Pharmaceuticals, Inc.


title:
A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer

 Etude de phase III, randomisée, contrôlée, multicentrique, à 3 bras, évaluant l'osimertinib en monothérapie néoadjuvante ou en association à une chimiothérapie, par rapport à une chimiothérapie seule standard, pour le traitement des patients atteints d'un cancer du poumon non à petites cellules résécable avec mutations du récepteur de facteur de croissance épidermique EGFR (NeoADAURA)

acronym: NeoADAURA

lead_sponsor: AstraZeneca AB


title:
A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A

 Etude en ouvert de phase II/III, multicentrique et internationale, visant à évaluer l'efficacité et la sécurité d'emploi de l'ALXN1101 chez des nouveau-nés présentant un déficit en cofacteur molybdène (MoCoD) de type A

lead_sponsor: Alexion Pharma GmbH


title:
An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in preceding studies with LOU064

 Etude d’extension, multicentrique, en ouvert, évaluant la tolérance et la sécurité d’emploi à long terme de LOU064 chez les patients éligibles souffrant d’urticaire chronique spontanée (UCS) et ayant participé à des études précédentes portant sur LOU064

lead_sponsor: Novartis Pharma AG


title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.

acronym: ESCALADE

lead_sponsor: Acerta Pharma B.V. (A Member of the AstraZeneca Group)


title: Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.

lead_sponsor: ITALFARMACO S.p.A.


title:
A randomized, open-label, Phase 2 study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma

 Etude de phase II, randomisée, en ouvert, comparant 2 schémas thérapeutiques de l'irinotécan nanoliposomal (nal-IRI) avec un traitement par nab-paclitaxel et gemcitabine chez des patients présentant un adénocarcinome pancréatique métastatique non précédemment traité

lead_sponsor: Merrimack Pharmaceuticals, Inc.


title:
An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/p110δ- activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)

 Etude d’extension, en ouvert, non randomisée, évaluant la sécurité d'emploi, la tolérance et l’efficacité à long terme ainsi que la pharmacocinétique de CDZ173 (leniolisib) chez des patients atteints d’APDS/PASLI (syndrome de PI3K-delta activée/déficit immunitaire, lymphadénopathie et cellules T sénescentes dus à des mutations activatrices de p110-delta)

acronym: Extension to the study of safety and efficacy of CDZ173 in patients with APDS/PASLI

lead_sponsor: Novartis Pharma Services AG


title: A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy

lead_sponsor: Amgen Inc.


title:
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately Active Ulcerative Colitis

 Étude randomisée, en double aveugle, contrôlée par placebo, sur 52 semaines, visant à évaluer l’efficacité et la sécurité d’emploi de l’étrasimod chez des patients atteints de rectocolite hémorragique active modérée

acronym: GLADIATOR

lead_sponsor: Arena Pharmaceuticals, Inc.


title: A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension.

acronym: The TARGET BP I Trial

lead_sponsor: Ablative Solutions, Inc


title:
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)

 Étude de phase 3, internationale, multicentrique, randomisée en double aveugle, portant sur le carboplatine-paclitaxel en association avec l’INCMGA00012 ou un placebo chez des patients atteints d’un carcinome épidermoïde du canal anal métastatique ou en récidive locale non opérable, n’ayant pas été précédemment traité s par une chimiothérapie systémique (POD1UM-303/InterAACT 2)

lead_sponsor: Incyte Corporation


title: An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with  ceritinib.


title:
An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment

 Etude d'extension, multicentrique, en ouvert, pour le suivi de l’innocuité à long terme de patients, recevant le Tafinlar (dabrafenib) et/ou le Mekinist (trametinib), dans le cadre d’une étude, sponsorisée par Novartis ou GSK et ayant atteint son objectif, et qui tirent un bénéfice de la poursuite du traitement selon le médecin-investigateur


title:
A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE

 Essai clinique de phase Ib/IIa multicentrique, en ouvert, visant à évaluer la sécurité d’emploi et l’efficacité de l’anticorps humain anti-CD38 MOR202 dans le cadre du traitement de la glomérulopathie  extramembraneuse avec anticorps anti-PLA2R (GEMa) – M-PLACE

lead_sponsor: MorphoSys AG


title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism

lead_sponsor: Ascendis Pharma Bone Diseases A/S


title: DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: Pathogenesis of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) in Decompensated Cirrhotic Subjects with Systemic Inflammation and ACLF

acronym: ALADDIN

lead_sponsor: Instituto Grifols S.A.


title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus

acronym: Ertugliflozin T2DM Pediatric Study (MK-8835/PF-04971729)

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc

status: Prematurely Ended


title: A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

lead_sponsor: Agenus Inc.


title:
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight

 Traitement par brodalumab selon un schéma posologique adaptable par rapport à un traitement standard par brodalumab pendant 52 semaines chez des patients atteints de psoriasis en plaques modéré à sévère et pesant au moins 120 kg

acronym: ADJUST

lead_sponsor: LEO Pharma A/S


title:
A Phase 2/3, Multicenter, Double-Blind, Randomized Study to
 Determine the Efficacy and Safety of DNL310 vs Idursulfase in
 Pediatric Participants With Neuronopathic or Non-Neuronopathic
 Mucopolysaccharidosis Type II

lead_sponsor: Denali Therapeutics Inc.


title:
BRENTUXIMAB VEDOTIN ASSOCIATED WITH CHEMOTHERAPY IN UNTREATED PATIENTS WITH STAGE I/II UNFAVOURABLE HODGKIN LYMPHOMA - A RANDOMIZED PHASE II LYSA-FIL-EORTC INTERGROUP STUDY

 Brentuximab vedotin associé à la chimiothérapie chez des patients atteints de lymphome de hodgkin stade I/II défavorable au diagnostic.
 Une étude randomisée de phase II de l’intergroupe LYSA-FIL-EORTC.

acronym: BREACH

lead_sponsor: LYSARC


title: An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Pemphigus

acronym: ADDRESS+

lead_sponsor: argenx BV


title: A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)

acronym: PROMIS II

lead_sponsor: Zambon S.p.A.


title: A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2)

acronym: Refer to the protocol

lead_sponsor: Hutchison MediPharma Limited


title:
A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy

 Etude multicentrique de 52 semaines, randomisée, en double aveugle, contrôlée
 par placebo évaluant l’efficacité et la sécurité d’emploi du ligélizumab (QGE031)
 dans la diminution de la sensibilité à l’arachide chez des patients allergiques à
 l’arachide

lead_sponsor: Novartis Pharma AG


title: An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

lead_sponsor: IONIS PHARMACEUTICALS, INC.


title:
A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy.

 Etude clinique de preuve de concept randomisée, à 3 groupes parallèles, avec traitement en ouvert et posologies en aveugle, visant à étudier l'efficacité et la sécurité d’emploi du LNP023 par rapport au rituximab dans le traitement des patients atteints de glomérulonéphrite extra-membraneuse idiopathique.


title:
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia

 Étude de phase III, randomisée, en double aveugle, destinée à évaluer l'efficacité de l'Uproleselan administré en association avec la chimiothérapie versus la chimiothérapie seule chez des patients atteints de leucémie myéloïde aiguë récidivante/réfractaire.

lead_sponsor: GlycoMimetics, Inc.


title:
Phase IIb, Placebo-Controlled, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB) Single Implantation in Tibial Fracture

 Étude de phase IIb, contrôlée par placebo, randomisée, en double aveugle, multicentrique, visant à évaluer l’efficacité et la sécurité d’emploi d’une implantation unique de cellules ostéoblastiques allogéniques (ALLOB®) dans la fracture du tibia

lead_sponsor: Bone Therapeutics S.A.


title:
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK).
 P/024/2021

acronym: EPPIK

lead_sponsor: Travere Therapeutics, Inc.


title: A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer

acronym: Troika

lead_sponsor: Prestige BioPharma Pte Ltd


title:
An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).

 ÉTUDE D’EXTENSION EN OUVERT, NON RANDOMISEE, MULTICENTRIQUE VISANT A EVALUER L’EFFICACITE ET LA SECURITE D’EMPLOI A LONG TERME DE L’APL-2 CHEZ DES PATIENTS ATTEINTS D’HEMOGLOBINURIE PAROXYSTIQUE NOCTURNE (HPN)

lead_sponsor: Apellis Pharmaceuticals, Inc.


title:
A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent  participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744

 Une étude d’extension en ouvert, multicentrique, à bras unique, visant à évaluer la sécurité d’emploi à long terme du GSK3511294 (dépémokimab) chez des patients adultes et adolescents atteints d’asthme sévère présentant un phénotype éosinophilique et issus des études 206713 ou 213744

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma

acronym: YOBI

lead_sponsor: STALLERGENES


title: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)

acronym: ARMADA 2000

lead_sponsor: Rafael Pharmaceuticals, Inc.


title:
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer

 Etude contrôlée randomisée évaluant le traitement d’entretien par S-1 dans le cancer oesophagogastrique métastatique

acronym: MATEO (Maintenance Teysuno in esophagogastric carcinoma)

lead_sponsor: AIO-Studien-gGmbH


title: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

lead_sponsor: Sellas Life Sciences


title: A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma

lead_sponsor: ALK-Abelló A/S


title: Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II

acronym: Triac Trial II

lead_sponsor: Rare Thyroid Therapeutics International AB


title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

lead_sponsor: Enanta Pharmaceuticals, Inc.


title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

lead_sponsor: Galderma S.A.


title: A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects

acronym: Firibastat in treatment-RESistant Hypertension (FRESH)

lead_sponsor: Quantum Genomics


title: A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT)

lead_sponsor: Albireo AB


title: An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

acronym: AdAPT: Adenovirus after Allogeneic Pediatric Transplantation

lead_sponsor: Chimerix, Inc


title: A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes Mellitus

lead_sponsor: Diamyd Therapeutics AB


title: A 24-month randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of sotrastaurin (STN) combined with tacrolimus (TAC) vs a tacrolimus / mycophenolate mofetil (MMF) - based control regimen in de novo liver transplant recipients

lead_sponsor: Novartis Pharma Services AG


title: An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer"

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A Phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens.

acronym: FORTIS-M

lead_sponsor: Agennix Incorporated


title: A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80mg as compared to amlodipine/valsartan 5/40mg or to amlodipine 5mg once daily in elderly patients with essential hypertension not adequately controlled after four weeks on amlodipine 5mg once daily


title: A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1

lead_sponsor: Schering-Plough Research Institute, a Division of Schering Corporation


title: A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF)

acronym: ASSURE-AF

lead_sponsor: AstraZeneca AB


title: A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07

lead_sponsor: Infinity Pharmaceuticals, Inc


title:
30-day, open-label, active-controlled, randomized study of the safety, efficacy and the
 pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young
 children with various manifestations of venous thrombosis

acronym: EINSTEIN Junior Phase II-part B: oral rivaroxaban in young children with venous thrombosis

lead_sponsor: Bayer HealthCare AG


title: ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin)

acronym: ENABLE 2

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.

lead_sponsor: BioPartners GmbH


title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia

lead_sponsor: Merck & Co., Inc.


title: Trial consisting of an 8-week double-blind placebo-controlled part to evaluate efficacy, safety, tolerability and pharmacokinetics of prucalopride in paediatric subjects with functional constipation, aged ≥6 months to <18 years, followed by a 16-week open-label comparator (PEG) controlled part, to document safety and tolerability up to 24 weeks

acronym: Not applicable

lead_sponsor: Shire-Movetis NV


title: A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study

acronym: IMPRES

lead_sponsor: Novartis Pharma AG


title: A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 μg b.i.d.) as an active control.


title: A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit

lead_sponsor: AB Science


title:
Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy

 Étude randomisée de phase II comparant la vinorelbine orale en monothérapie administrée selon deux schémas différents, chez des patients atteints de cancer bronchique non à petites cellules avancé pour lesquels la chimiothérapie à base de platine n'est pas indiquée.

acronym: TEMPO LUNG 01

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected with Respiratory Syncytial Virus

acronym: PLUM

lead_sponsor: Janssen-Cilag International NV


title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE

lead_sponsor: Pfizer Inc.


title: A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid-Dependent Subjects.

lead_sponsor: Schering-Plough Research Institute


title: Efficacy and safety of oral budesonide-MMX™ (CB-01-02) 6 mg and 9 mg extended release tablets in patients with mild or moderate active ulcerative colitis.  A multicentre, randomised, double-blind, double-dummy, comparative study versus placebo with an additional reference arm evaluating entocort®EC

lead_sponsor: COSMO Technologies Ltd


title: A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with a  prior statin treatment. (IN-CROSS).

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, Simulect® and corticosteroids in de novo adult renal transplant recipients

lead_sponsor: Novartis Pharma Services AG


title: A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis.

acronym: DOSE

lead_sponsor: Schering Plough Research Institute, a Division of Schering Corporation


title: A 6-month, double-blind, randomized, placebo-controlled, parallel group outpatient trial, investigating the efficacy and safety of Org 50081 in adult patients with chronic primary insomnia.

acronym: AQUAMARINE

lead_sponsor: NV Organon


title: A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy

lead_sponsor: CytRx Corporation


title:
A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY
 TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN
 INADEQUATE RESPONSE TO METHOTREXATE


title: A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment

lead_sponsor: AB SCIENCE


title:
Comparison of the Efficacy and Safety of Infliximab, as Monotherapy or in Combination With Azathioprine, Versus Azathioprine Monotherapy in Moderate to Severe Active Ulcerative Colitis (Part 1).
 Comparison of Maintenance Versus Intermittent Infliximab Treatment in Maintaining Remission:   A Follow-up of Efficacy and Safety (Part 2)

lead_sponsor: Schering-Plough Research Institute, a division of Schering Corporation


title: A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy

lead_sponsor: Bayer HealthCare AG


title: A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa-2a and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials

lead_sponsor: Merck & Co., Inc.


title: A Randomised Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukaemia

lead_sponsor: Clavis Pharma


title: An open-label, multicentre, randomised phase II study of pazopanib in combination with pemetrexed in first-line treatment of subjects with predominantly non-squamous cell stage IIIBwet/IV non-small cell lung cancer

lead_sponsor: GlaxoSmithKline R&D Limited


title: A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control


title: "A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients"


title: A Randomized, Multicenter, Phase III Study Comparing the Combination of  Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer

lead_sponsor: GlaxoSmithkline Research & Development Limited


title:
Assessment of Anatomical and Functional Outcomes in Patients Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
 (VMT/sVMA)

lead_sponsor: Alcon Research, Ltd.


title: Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee

lead_sponsor: Janssen-Cilag International N.V.


title: A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

acronym: A Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Prodromal AD (APECS)

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease

acronym: A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)

lead_sponsor: NeuroSearch Sweden AB


title: Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women


title: Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) when Exposed to plasma-derived von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial.

acronym: SIPPET

lead_sponsor: FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI


title: A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Infection


title: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients

lead_sponsor: Laboratoires Merck Sharp & Dhome-Chibret


title: An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection

lead_sponsor: Novartis Pharma GmbH


title: A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia. A collaborative study of the Interfant network.

lead_sponsor: Princess Máxima Center for Pediatric Oncology


title: A prospective randomised phase III study of androgen deprivation therapy with or without local  radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.

lead_sponsor: UNICANCER


title: A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)

lead_sponsor: Genta Incorporated


title: Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice.

lead_sponsor: Integrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.


title: A 12-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

acronym: MONT BLANC

lead_sponsor: Novartis Pharma Services AG


title: A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.

acronym: Extended Release Niacin/Laropiprant – Lipids


title: A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease


title: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose- Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin

lead_sponsor: Laboratoires Merck Sharp & Dohme-Chibret


title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Peripheral Spondyloarthritis

lead_sponsor: Abbott GmbH & Co. KG


title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.

lead_sponsor: BioPartners GmbH


title: A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study  the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination with Metformin)


title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome.

acronym: FMS Europe

lead_sponsor: Pierre Fabre Medicament


title: A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients with Locally-Advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-cancer Therapy

lead_sponsor: AstraZeneca AB


title: A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 3 PARALLEL ARMS, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NOVA22007 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED IN PAEDIATRIC PATIENTS WITH ACTIVE SEVERE VERNAL KERATOCONJUNCTIVITIS WITH SEVERE KERATITIS

lead_sponsor: Novagali Pharma S.A.S.


title: A Multicenter, Randomized, Controlled, Two-Arm, Phase III Study to Evaluate the Safety and Efficacy of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the SPONSOR or Merck)


title: A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post-treatment safety follow-up in moderate to severe dry eye patients

lead_sponsor: DRUG DELIVERY SOLUTIONS ApS (PART OF MC2 BIOTEK GROUP)


title: A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via  Twisthaler®, in patients with COPD.


title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura


title: Two-arm, randomized, open-label, phase IIIb study investigating the safety of a 3 hour i.p. infusion of catumaxomab with and without prednisolone premedication in patients with malignant ascites due to epithelial cancer

acronym: CASIMAS

lead_sponsor: Fresenius Biotech GmbH


title: A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®

lead_sponsor: Laboratoires SMB S.A.


title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS IN PEDIATRIC SUBJECTS AGED 2 TO 17 YEARS

lead_sponsor: Pfizer Inc. 235 East 42nd Street, New York, NY 10017


title: An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimus For Fast Expanded aCcess in TSC SEGA

acronym: EFFECTS STUDY


title: A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

lead_sponsor: MedImmune, LLC


title: A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day in combination with bortezomib and dexamethazone to placebo in combination with bortezomib and dexamethazone in the treatment of patients with relapsing multiple myeloma who received one previous therapy

lead_sponsor: AB Science


title: A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor resistant to imatinib


title:
A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer

 Etude de phase 3, prospective, multicentrique, randomisée, en double aveugle, contrôlée, avec 2 groupes parallèles, visant à comparer l’efficacité et la tolérance de masitinib en association avec FOLFIRI (irinotecan, 5-fluorouracil et acide folinique) versus placebo en association avec FOLFIRI, chez des patients atteint d’un cancer colorectal métastatique en 2ème ligne de traitement


title: Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label extension for patients completing study 3119002

acronym: REFALS-ES

lead_sponsor: Orion Corporation


title: A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

lead_sponsor: Orphazyme A/S


title: A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome

acronym: PATIDEGIB study

lead_sponsor: PellePharm, Inc.


title: A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%)

lead_sponsor: Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company


title: A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma

acronym: CheckMate 459

lead_sponsor: Bristol-Myers Squibb International Corporation


title: An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment

lead_sponsor: Novartis Pharma Services AG


title:
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)

 Étude clinique de phase III, randomisée, comparant la lurbinectédine (PM01183) à la doxorubicine liposomale pégylée ou au topotécan chez des patientes présentant un cancer de l’ovaire résistant au platine (Etude CORAIL)

acronym:
CORAIL Trial

 Etude CORAIL

lead_sponsor: Pharma Mar S.A., Sociedad Unipersonal


title:
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study- the CARAVAGGIO study.

 APIXABAN POUR LE TRAITEMENT DE LA THROMBOEMBOLIE VEINEUSE CHEZ LES PATIENTS CANCÉREUX : UNE ÉTUDE PROSPECTIVE ALÉATOIRE AVEC CRITÈRE À L'INSU (PROBE) - ÉTUDE CARAVAGGIO

acronym:
CARAVAGGIO

 CARAVAGGIO

lead_sponsor: FONDAZIONE FADOI


title: A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory Syncytial Virus Infection

acronym: PLUM Follow-up

lead_sponsor: Janssen-Cilag International NV


title:
A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects with Previously-Treated Indolent Non-Hodgkin Lymphoma

 Etude de phase 3, randomisée, en double aveugle comparant le duvelisib administré en association avec du rituximab et de la bendamustine contre placebo administré en association avec du rituximab et de la bendamustine chez des patients atteints de lymphome non hodgkinien indolent antérieurement traité

lead_sponsor: Infinity Pharmaceuticals, Inc.


title: A phase 3, randomized, double-blind trial of nivolumab in combination with intravesical BCG versus standard of care BCG alone in participants with high-risk non-muscle invasive bladder cancer that is persistent or recurrent after treatment with BCG


title: Efficacy and tolerance of the emollient cream V0034 CR in the symptomatic treatment of ichthyosis in children. International, multicentric, randomised, controlled, double blind study, in parallel groups V0034 CR versus vehicle.

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)

lead_sponsor: sanofi-aventis Recherche & D2veloppement

status: Suspended by CA


title: A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiency

lead_sponsor: OPKO Biologics Ltd.


title: A 52 week, randomised, double blind, multinational, multicentre, 4-arm parallel group trial to assess the efficacy and safety of 3 doses of CHF 6532 (10, 25 or 50 mg BID) compared to placebo on top of standard of care in subjects with uncontrolled severe eosinophilic asthma.

lead_sponsor: Chiesi Farmaceutici S.p.A.


title: A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction

acronym: RESPOND

lead_sponsor: Eli Lilly & Company Limited


title: A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia

lead_sponsor: Janssen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium


title: A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 μg plus formoterol 6 μg/actuation), 2 puffs b.i.d., versus beclomethasone diproprionate HFA (250 μg/actuation), 4 puffs b.i.d., versus Seretide® 500/50 (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d., in patients with severe asthma

lead_sponsor: CHIESI FARMACEUTICI S.p.A.


title: ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin)

acronym: ENABLE 1

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A phase III study to compare SonoVue®  enhanced myocardial echocardiography (MCE) to single photon emission computerized tomography (ECG-GATED SPECT), at rest and at peak of low-dose Dipyridamole stress test, in the assessment of significant coronary artery disease (CAD) in patients with suspect or known CAD using Coronary Angiography as Gold Standard

acronym: SonoVue MCE vs SPECT

lead_sponsor: Bracco Imaging S.p.A.


title: A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally once during an acute migraine attack of moderate or severe intensity

lead_sponsor: Boehringer Ingelheim France


title: Safety and Efficacy of Exenatide Once Weekly Injection versus Metformin, Dipeptidyl  Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients with Type 2 Diabetes

acronym: GWCH

lead_sponsor: Eli Lilly and Company


title: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension

lead_sponsor: United Therapeutics Corporation


title: Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

acronym: CILAB

lead_sponsor: Sanofi-Aventis Recherche et Développement


title: A Phase III, Multicentre, Open Label, Flexible dose, Long term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (incorporating a Comparison with Sevelamer).

lead_sponsor: Mitsubishi Pharma Corporation


title: A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis

lead_sponsor: Shire Pharmaceutical Development Ltd


title: A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12 months  administration of 2g per day of strontium ranelate versus alendronate 70mg per week on bone remodelling and bone safety assessed by histomorphometry in women with postmenopausal osteoporosis

lead_sponsor: Institut de Recherches Internationales Servier


title: A 16-Week International, Multicenter, Double-Blind,  Randomized, Placebo Controlled  Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension

acronym: FREEDOM-C


title: A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NOVO KIDNEY ALLOGRAFT RECIPIENTS

lead_sponsor: Pfizer Inc. 235 East 42nd Street, New York, NY10017


title: Open-Label Extension Study to Assess the Safety of a Fixed Dose of Subcutaneous Methylnaltrexone in Subjects With Advanced Illness and Opioid-Induced Constipation

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc., Global Medical Affairs


title: A RANDOMISED, DOUBLE-BLIND, ADD-ON STUDY OF HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE HYPERTENSION NOT ACHIEVING TARGET BLOOD PRESSURE ON OLMESARTAN MEDOXOMIL/AMLODIPINE FIXED DOSE COMBINATION 40/10 MG ALONE

lead_sponsor: DAIICHI SANKYO EUROPE GmbH


title: An evaluation of the Ocular Surface Health in Subjects Using DuoTrav APS Eye Drops Solution Versus XALACOM® EYE Drops Solution

lead_sponsor: Alcon Research, Ltd.


title: An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial-Onset Seizures.

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schizophrenia

lead_sponsor: Janssen-Cilag International N.V.


title: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, due to left heart disease, undergoing cardiac surgery

lead_sponsor: Actelion Pharmaceuticals Ltd


title: A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjector and the Etanercept Prefilled Syringe) in Patients with Psoriasis.

lead_sponsor: Wyeth Pharmaceuticals France


title: A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

acronym: Spinnaker

lead_sponsor: Eli Lilly and Company limited


title: A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course.

acronym: Atacicept frequent MRI study in RMS

lead_sponsor: Merck Serono International S.A.


title: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated with Valproate or Lithium and in Need of Further Clinical Improvement.

lead_sponsor: Bristol Myers Squibb International Corporation


title: A Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional Health Outcomes


title: A multicenter, randomized, open label,  active-comparator  controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin,  thiazolidinedione or a combination of both

lead_sponsor: F. Hoffmann-La Roche Ltd.


title: A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy

lead_sponsor: GlaxoSmithKline Research & Development Ltd.


title: A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis

lead_sponsor: AOP Orphan Pharmaceuticals AG


title: Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease

lead_sponsor: Eisai Ltd


title: A phase II, multicentre, randomised, assessor.blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f) in oligo-anovulatory infertile women undergoing ovulation induction (OI)

acronym: AS900672-Enriched Phase II in OI

lead_sponsor: Merck Serono SA International


title: Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given x 10 days With Omeprazole in Eradication of Helicobacter pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given x 7 days

lead_sponsor: Axcan Pharma Inc.


title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR VERSUS ORAL GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECEIPIENTS OF ORTHOTOPIC LIVER TRANSPLANTS

lead_sponsor: ViroPharma Incorporated


title: A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Assess the Time to Response to Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy.

lead_sponsor: Shire Pharmaceutical Development Ltd.


title:
A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Colitis (UC) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy.
 Revised Protocol 01, incorporating Protocol Amendment 02 (Version 1.0, Date 06-Dec-2006) and Administrative Letter 01.

lead_sponsor: Bristol-Myers Squibb International Corporation


title: An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using once monthly subcutaneous injections of RO0503821 in patients with chronic kidney disease who are not on dialysis

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A Phase 3, Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery


title: D1532C00016: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line Patients with KRAS Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)

lead_sponsor: AstraZeneca AB


title: An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have completed the RESTORE trial

acronym: RESTORE EXTENSION

lead_sponsor: Novartis Pharma Services AG


title: Safety and Efficacy of Exenatide Once Weekly versus Liraglutide in subjects with type 2 diabetes and inadequate glycemic control treated with lifestyle modification and oral antidiabetic medications

acronym: GWDE

lead_sponsor: Eli Lilly and Company


title: International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia

acronym: INTERFANT 06

lead_sponsor: Dutch Childhood Oncology Group


title: A Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures

acronym: CaReS (Carisbamate Retention Study)

lead_sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC


title: A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of three dosages of Lu AA21004, in acute treatment of Major Depressive Disorder.

acronym: Not applicable

lead_sponsor: H. Lundbeck A/S


title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2 093) AS THERAPY FOR PATIENTS WITH POST-HERPETIC NEURALGIA: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL TRIAL

lead_sponsor: BIAL - Portela & Ca, S.A.


title: A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis involving hands and/or feet, with or without pustules.

acronym: TRUST study: Raptiva ® in hands & foot psoriasis

lead_sponsor: Merck Serono International SA


title: Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas.  A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas, followed by a 52-week safety study in patients with psoriasis vulgaris on the face and on the intertriginous areas.

lead_sponsor: LEO Pharma A/S


title: A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP 2)/Calcium Phosphate Matrix (CPM) in Closed Diaphyseal Tibial Fractures

lead_sponsor: Wyeth Pharmaceuticals Inc.


title: A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochemical Failure (PSA increase) after Radical Therapy with Curative Intent (ARTS – AVODART after Radical Therapy for prostate cancer Study)

acronym: ARTS

lead_sponsor: GlaxoSmithKline Research and Development Ltd


title: A Phase II study of Tarceva® in Combination with Avastin® versus chemotherapy plus Avastin® in 1st line advanced NSCLC patients

lead_sponsor: F. Hoffmann-La Roche


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder.

acronym: Lamda 2

lead_sponsor: Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium


title: A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder


title: A double blind, randomized, placebo controlled, parallel group dose range exploration study of Sativex® in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy.

lead_sponsor: GW Pharma Ltd.


title: An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s Lymphoma

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc


title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Following Failure of at Least Imatinib and Sunitinib

lead_sponsor: Infinity Pharmaceuticals, Inc.


title: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUATE RESPONSE TO TNF INHIBITORS

lead_sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017


title: Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy

lead_sponsor: AstraZeneca AB


title: A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson’s disease.

acronym: The Vermeer study

lead_sponsor: Solvay pharmaceuticals


title: A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Treatment-Naïve Children and Adolescents. (ADHD-LIFE Study)

acronym: (ADHD-LIFE Study)

lead_sponsor: Eli Lilly and Company


title: An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly  vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis

lead_sponsor: F. Hoffmann-La Roche Ltd


title: Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension

lead_sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.


title: Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3

lead_sponsor: Actelion Pharmaceuticals Ltd


title: A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with visual impairment due to diabetic macular edema

acronym: RESTORE

lead_sponsor: Novartis Pharma Services AG


title: A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in subjects with chronic genotype 1 hepatitis C infection who failed prior pegylated interferon plus ribavirin treatment.

acronym: REALIZE

lead_sponsor: Tibotec BVBA


title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE

lead_sponsor: Pfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ


title: A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle  Following Cataract Surgery in Diabetic Retinopathy Patients

acronym: Macular Edema Incidence/Severity Reduction with NEVANAC®

lead_sponsor: ALCON RESEARCH, LTD.


title: A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART)

acronym: CONSORT RCT in ART

lead_sponsor: Merck Serono International S.A.


title: An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A Phase 3b, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients with Prostate Cancer

lead_sponsor: Ferring Pharmaceuticals A/S


title: Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma

acronym: forodesine in CTCL

lead_sponsor: BioCryst Pharmaceuticals, Inc.


title: A PHASE 2, RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS INJECTIONS OF E10030 (ANTI-PDGF PEGYLATED APTAMER) GIVEN IN COMBINATION WITH LUCENTIS® IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

acronym: REGRESS

lead_sponsor: OPHTHOTECH CORPORATION


title: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock

acronym: PROWESS-SHOCK


title: A Phase II, Dose-Escalation to rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer.

acronym: RACHEL

lead_sponsor: F. Hoffmann-La Roche


title: A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

lead_sponsor: Amgen Inc


title: An open-label extension study following a double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizures.

lead_sponsor: Eisai Ltd


title: Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.


title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP MULTI-CENTER COMPARATIVE FLEXIBLE-DOSE STUDY OF PREGABALIN VERSUS LEVETIRACETAM AS ADJUNCTIVE THERAPY TO REDUCE SEIZURE FREQUENCY IN SUBJECTS WITH PARTIAL SEIZURES (A0081157).

lead_sponsor: Pfizer Inc,East 42nd street,New york, NY10017, USA


title: A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN.

lead_sponsor: Pfizer


title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagliflozin) Compared with Placebo in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy

acronym: The CANTATA-MP Trial

lead_sponsor: Janssen-Cilag International NV


title: Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis

lead_sponsor: Eli Lilly and Company


title: Superiority of insulin glargine Lantus vs. NPH: “Treat to Normoglycemia concept”. Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-naïve People with Type 2 Diabetes Mellitus Treated with at Least One OAD and Not Adequately Controlled.

acronym: LANCELOT

lead_sponsor: SANOFI-AVENTIS GROUPE


title: A 12-week, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of prucalopride in subjects with chronic non-cancer pain suffering from opioid induced constipation

lead_sponsor: Movetis NV


title:
A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis

 Etude de phase 3 randomisée d’une durée de 52 semaines, en double aveugle, contrôlée par placebo évaluant la sécurité d'emploi et l'efficacité de la relamoreline chez des patients atteints de gastroparésie diabétique

acronym:
Diabetic Gastroparesis Study 4

 Étude 4 évaluant la gastroparésie diabétique

lead_sponsor: Allergan Ltd.


title: Risk stratified randomized controlled trial in paediatric Crohn’s Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive disease course, respectively – a treatment strategy

acronym: REDUCE-RISKincd-PIBD-TRIAL

lead_sponsor: PIBDNet


title: A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma

acronym: SUNNIFORECAST

lead_sponsor: Goethe University Frankfurt

lead_sponsor_type: academique


title:
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

 Étude de phase 3, multicentrique, ouverte, randomisée comparant le tivozanib au soréfanib chez des patients présentant un cancer du rein métastatique réfractaire

lead_sponsor: AVEO PHARMACEUTICALS, INC.


title: Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)

acronym: Phase 3 Study of Pembrolizumab with/without Epacadostat in second line Urothelial Carcinoma

lead_sponsor: Incyte Corporation


title: A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE-119)

acronym: A Study of Single Agent Pembrolizumab vs Single Agent Chemotherapy for mTNBC

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc


title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

lead_sponsor: Cougar Biotechnology, Inc


title:
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
 Revised Protocol 01 (version 4.0 dated 21-Apr-08), incorporating Amendment 02 (version 1.0 dated 21-Apr-08)

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel)

lead_sponsor: F. Hoffmann La-Roche Ltd


title: A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (MabThera/Rituxan) in the inhibition of joint structural damage assessed by magnetic resonance imaging in patients with rheumatoid arthritis and inadequate response to methotrexate - the SCORE study.

acronym: SCORE

lead_sponsor: F. Hoffman-La Roche Ltd.


title: A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of Metformin and Glimepiride (AWARD-2: Assessment of Weekly AdministRation of LY2189265 in Diabetes-2)

acronym: GBDB

lead_sponsor: Eli Lilly & Company - Indianapolis


title:
A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism
 Revised Protocol Number: 01, Incorporates amendment(s) 02

lead_sponsor: Bristol-Meyers Squibb International Corporation


title: A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures

lead_sponsor: SCHWARZ BIOSCIENCES, Inc.


title: Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis

lead_sponsor: Amgen Inc


title: A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

lead_sponsor: Janssen-Cilag International N.V.


title:
PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

 ÉTUDE DE PHASE IB/III MULTICENTRIQUE PORTANT SUR L’AVÉLUMAB (MSB0010718C) DANS DES ASSOCIATIONS THÉRAPEUTIQUES INCLUANT UN AGONISTE IMMUNITAIRE, UN MODULATEUR ÉPIGÉNÉTIQUE, UN ANTAGONISTE DE CD20 ET/OU UNE CHIMIOTHÉRAPIE CLASSIQUE CHEZ DES PATIENTS ATTEINTS DE LYMPHOME DIFFUS À GRANDES CELLULES B (LDGCB) RÉCIDIVANT OU RÉFRACTAIRE

acronym: JAVELIN DLBCL

lead_sponsor: Pfizer Inc, 235 East 42nd Street, New York, NY 10017


title: GRACE (Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe). Workpackage 10: Antibiotic Trial One

acronym: GRACE AT ONE

lead_sponsor: University of Southampton


title: Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without BSI-201 (SAR240550) (a PARP1 Inhibitor) in Patients with Previously Untreated Stage IV Squamous Non Small Cell Lung Cancer (NSCLC)

lead_sponsor: BiPar Sciences, Inc.


title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to TNF-α antagonist therapy

acronym: Investigating efficacy of ofatumumab in RA patients with inadequate response to TNF-α antagonist

lead_sponsor: Genmab A/S


title: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes

acronym: SAVOR

lead_sponsor: AstraZeneca AB


title: A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a Selected Population with Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer (THYME)

acronym: THYME


title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)

lead_sponsor: Alexion Pharmaceuticals, Inc.


title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric
 Subjects with Moderate to Severe Ulcerative Colitis.

lead_sponsor: Abbvie Deutschland GmbH & Co. KG


title: A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 Months in Subjects Undergoing Bilateral Nerve-Sparing Radical Prostatectomy

acronym: LVIK

lead_sponsor: Eli Lilly and Company Limited


title: A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (1mg, 5mg, 10mg, 25mg, and 50mg) administered orally once daily over 12 weeks compared double blind to placebo with an additional open-label sitagliptin arm in type 2 diabetic patients with insufficient glycemic control despite metformin therapy

lead_sponsor: Boehringer Ingelheim France


title:
FondaparinUx Trial with UFH during Revascularization in Acute Coronary Syndromes (FUTURA)
 A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high risk patients with UA/NSTEMI initially treated with subcutaneous fondaparinux and referred for early coronary angiography (OASIS 8)

acronym: OASIS 8 (FUTURA)

lead_sponsor: GlaxoSmithKline R & D


title: A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component

acronym: Neptune

lead_sponsor: Astellas Pharma Europe B.V.


title: Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study.

lead_sponsor: Institut de Recherches Internationales Servier


title: An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)


title: A Randomized, Controlled, Open- label Study Evaluating the Efficacy and Tolerability of AMG 531 versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects with Immune (Idiopathic) Thrombocytopenic Purpura

lead_sponsor: Amgen Inc.


title: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure

acronym: ASCEND-HF

lead_sponsor: Janssen-Cilag International NV,Turnhoutseweg 30, 2340  Beerse, Belgium


title: An eight-week, multinational, multicenter, double-blind, active- and placebo-controlled clinical trial evaluating the efficacy and tolerability of three fixed doses of SSR125543 (20 mg daily, 50 mg daily and 100 mg daily) in outpatients with major depressive disorder.

acronym: AGATE

lead_sponsor: Sanofi-Aventis Recherche & Développement


title: Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease:  LY450139 versus Placebo

lead_sponsor: Eli Lilly and Company


title: TachoSil versus current practice in dura sealing techniques for the prevention of postoperative cerebrospinal fluid (CSF) leaks in patients undergoing skull base surgery: An open label, randomised, controlled, multicentre, parallel group efficacy and safety trial.

acronym: TASALL -TachoSil Against Liquor Leak

lead_sponsor: Nycomed Danmark ApS


title: A  Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected children (PENTA 18)

acronym: KONCERT

lead_sponsor: Paediatric European Network for Treatment of AIDS (PENTA) Foundation


title: A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus

lead_sponsor: Wyeth Pharmaceuticals


title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

lead_sponsor: Shire Human Genetic Therapies, Inc.


title: A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole versus other Atypical Antipsychotics in the Treatment of Schizophrenic Patients with Metabolic Syndrome

lead_sponsor: Bristol Myers Squibb International Corporation


title: A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity.

acronym: SONIC


title: A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) of squamous histology

lead_sponsor: Novartis Pharma Services AG


title: A Randomised Open Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in Patients with Newly Diagnosed Mantle Cell Lymphoma Who are Not Eligible for a Bone Marrow Transplant.

lead_sponsor: Janssen-Cilag International N.V.


title: An Open-Label, Phase IV, Multi-Centre Study to Investigate the Long-Term Safety and Efficacy of Subcutaneous Dynepo in Adult Patients with Anaemia Associated with Chronic Kidney Disease.

acronym: Dynepo long-term safety study

lead_sponsor: Shire


title: A twelve-month, multicenter, double-masked study of Travoprost / Brinzolamide fixed combination QD AM and Travoprost / Brinzolamide fixed combination QD PM versus COSOPT BID in patients with open-angle glaucoma or ocular hypertension

acronym: Travoprost / Brinzolamide Fixed Combination Once-Daily vs. COSOPT

lead_sponsor: Alcon Research, Ltd.


title: A Phase II, Double-Blind, Randomised Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma

lead_sponsor: AstraZeneca AB


title: A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease

lead_sponsor: Amicus Therapeutics, Inc.


title: Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens


title: Multicenter, Open-Label Study to Assess Early Response to Abatacept with Background Methotrexate Using Power Doppler Ultrasonography in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate


title: A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma

lead_sponsor: Clovis Oncology Inc


title:
A phase III, randomised, open label, active-controlled study of an
 interferon-free regimen of BI 207127 in combination with Faldaprevir
 and Ribavirin compared to Telaprevir in combination with pegylated
 interferon-a and ribavirin in treatment-naive patients with chronic
 genotype 1b Hepatitis C Virus infection.

lead_sponsor: Boehringer Ingelheim France


title: An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)

lead_sponsor: Astellas Pharma Europe B.V.


title: An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia


title:
Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism.

 Safety and efficacy of low molecular weight heparin for at least 72 hours followed by Dabigatran for the treatment of acute intermediate-risk pulmonary embolism PEITHO-2

lead_sponsor: JOHANNES GUTENBERG UNIVERSITY


title: A confirmatory, placebo-controlled, randomised, double-blind, single-dummy, parallel group, ratio-finding study in constipated pain patients to establish an optimal hydromorphone – naloxone ratio with an improved bowel function and a comparable analgesic efficacy compared to hydromorphone alone

acronym: Optimisation of Hydromorphone - Naloxone Ratio for the treatment of pain

lead_sponsor: Mundipharma Research GmbH & Co. KG


title: A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)

acronym: not applicable

lead_sponsor: Pfizer Ltd


title: A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in adult patients with  Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML - CP) who have suboptimal cytogenetic response (CyR) on imatinib.

lead_sponsor: Novartis Pharma Services


title: Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy “The COMBO - DN (COmbination vs Monotherapy of pregaBalin and dulOxetine in Diabetic Neuropathy) Study”

acronym: HMGQ

lead_sponsor: Eli Lilly and Company


title: A 3-PHASE STUDY TO EVALUATE SUSTAINED REMISSION AND PRODUCTIVITY OUTCOMES IN SUBJECTS WITH EARLY RHEUMATOID ARTHRITIS INITIATED ON TREATMENT WITH ETANERCEPT PLUS METHOTREXATE

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development


title: A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis.

acronym: MYCYC

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of TC-5214 (S mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy


title: Comparison of Two Different Treatment Strategies in Patients with Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy

acronym: HMGD(a)

lead_sponsor: Eli Lilly and Company Limited


title: A 52-week randomised, controlled, open label, multicentre, multinational treat-to-target trial comparing the efficacy and safety of SIBA and insulin glargine, both injected once daily in combination with oral anti-diabetic drugs (OAD), in subjects with type 2 diabetes mellitus currently treated with OAD(s) and qualifying for more intensified treatment

lead_sponsor: Novo Nordisk A/S


title: GAP Grazax Asthma Prevention

acronym: GAP

lead_sponsor: ALK-Abelló A/S


title: Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG. Pegasus

lead_sponsor: European Organisation for Research and Treatment of Cancer (EORTC)


title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

acronym: CONTESSA

lead_sponsor: Odonate Therapeutics, LLC


title:
A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

 Étude randomisée de phase III visant à comparer l’association IMO-2125 et ipilimumab versus ipilimumab seul chez des sujets présentant un mélanome réfractaire aux anticorps anti-PD-1

lead_sponsor: Idera Pharmaceuticals, Inc.


title: An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

acronym: PHYOX 3

lead_sponsor: Dicerna Pharmaceuticals Inc


title: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

lead_sponsor: Pharmacyclics Switzerland GmbH


title:
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY

 Étude multicentrique, en ouvert et à long terme portant sur la sécurité d’emploi de l’AR101, une immunothérapie de désensibilisation spécifique par voie orale, chez des patients ayant participé à une étude antérieure sur l’AR101

acronym:
Long-term Safety Study of AR101 CODIT™

 Étude de sécurité à long terme sur l’AR101 CODIT™

lead_sponsor: Aimmune Therapeutics, Inc.


title: A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with moderate to severe ulcerative colitis who have inadequate response, loss of response, or intolerance with at least one of the following agents: immunosuppressant treatment (i.e. azathioprine, 6-mercaptopurine, methotrexate), tumor necrosis factor alpha [TNF-α] inhibitors, vedolizumab, JAK inhibitors and/or corticosteroid treatment.

lead_sponsor: ABIVAX


title:
A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle-Invasive Bladder Cancer Patients  (POTOMAC)

 Etude ouverte, randomisée, multicentrique, de phase III évaluant l’association de durvalumab avec le Bacille de Calmette-Guerin (BCG) versus le BCG seul chez des patients non préalablement traités par BCG ayant une tumeur vésicale de haut risque n’infiltrant pas le muscle (POTOMAC)

acronym: POTOMAC

lead_sponsor: AstraZeneca AB